Abstract:Background: For patients with symptomatic intracranial and vertebral artery stenosis who receive endovascular treatment, in-stent restenosis (ISR) is associated with the recurrence of ischemic stroke. This study evaluated a drug-eluting stent (DES) vs. bare metal stent (BMS) for the treatment of symptomatic intracranial and vertebral artery stenosis. Methods: The trial was a multicenter, 1:1 randomized, prospective feasibility clinical trial with 10 participating centers in China from March 2014 to October 2015. Eligible patients had symptomatic intracranial and vertebral artery stenosis (70%−99%) and had medical drug treatment failure. The primary endpoint was the rate of in-stent restenosis at 180 days of randomization. The secondary endpoint was a composite of the following two outcomes: (1) ischemic stroke or transient cerebral ischemia (TIA) in the same territory as the presenting event (distal to the target lesion) between 30 days and 1 year after randomization and (2) successful stent implantation. The safety outcome was the presence of stroke in any territory and death within 30 days of randomization or adverse events. Group t -tests or Wilcoxon rank-sum tests were used for the intergroup comparison of quantitative data according to the data distribution. The chi-square test or exact probability method was used for the classification data. The Wilcoxon rank-sum test or CMH test was used for the categorical data. Results: We enrolled 188 patients at 10 medical centers in China (92 assigned to the DES group and 96 to the BMS group). The mean age of the 188 study participants was 61.6 years (range, 38–75 years); 152 participants (80.9%) were male. There were 28 patients (43.8%) with an ISR at 180 days in the BMS group and 10 patients (14.5%) in the DES group [risk difference, 29.3% (95% CI, 14.5%−44.0%); P = 0.001]. The percent of patients with ischemic stroke or TIA in the same territory between 30 days and 1 year was 5.2% (5/96) in the BMS group and 2.2% (2/92) in the DES group [risk difference, 3.0%; (95% CI, −2.3% to 8.2%); P = 0.354]. The percent of patients with successful stent implantation was 99.0% (95/96) in the BMS group and 97.8% (90/92) in the DES group [risk difference, 1.1%; (95% CI, −1.7% to 3.9%); P = 0.584]. In total, five patients (5.2%) in the BMS group and three patients (3.3%) in the DES group [risk difference, 1.9%; (95% CI, −2.3% to 6.1%); P = 0.721] had stroke in any territory and death within the 30-day follow-up. Total adverse events occurred 167 times in 72 patients (75.0%) in the BMS group compared with 114 times in 59 patients (64.1%) in the DES group [risk difference, 10.9%; (95% CI, −0.1% to 21.7%); P = 0.115]. Conclusions: Among patients with symptomatic intracranial arterial stenosis and vertebral artery stenosis, the use of a drug-eluting stent compared with a bare metal stent resulted in a decreased risk of ISR, similar successful stent implantation, and similar adverse events. These findings support the use of a drug-eluting stent for patients with symptomatic intracranial arterial stenosis and vertebral artery stenosis. Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=148272, identifier: ChiCTR2200055925.

Efficacy and Safety of Drug-Eluting Stent Implantation for the Treatment of In-Stent Restenosis Occurring Within Bare-Metal Stent and Drug-Eluting Stent

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis.

AS-160: Difference in Efficacy and Safety Profile of Drug-Eluting Stents in the Treatment of Intra-Stent Restenosis Secondary to Bare-Metal Stent Versus Drug-Eluting Stent Implantation

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

Drug-eluting Stents for Patients with Acute Coronary Syndromes: an Analysis of Long Term Outcome

Long-term outcomes of drug-eluting versus bare-metal stent for ST-elevation myocardial infarction.

Comparison of Drug-Eluting Stents with Bare Metal Stents Implantation for the Treatment of Acute ST-elevation Myocardial Infarction: 2-Year Clinical Outcomes from Single-Center Registry.

Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease.

Clinical Outcome after Management of Unprotected Left Main In-Stent Restenosis after Bare Metal or Drug-Eluting Stents

Drug-eluting stents versus bare-metal stents for intracranial atherosclerotic stenosis: a systematic review and meta-analysis

Effect of a Drug-Eluting Stent vs. Bare Metal Stent for the Treatment of Symptomatic Intracranial and Vertebral Artery Stenosis

Meta-analysis of long-term outcomes of drug-eluting stent implantations for chronic total coronary occlusions.

Comparison of Long-term Clinical Outcome between Drug-Eluting and Bare Metal Stents in Treating Large Coronary Vessel Lesions

Resultados a Longo Prazo De Eluição De Fármaco Versus Stent Metálico Para Infarto Do Miocárdio Com Elevação ST Long-term Outcomes of Drug-eluting Versus Bare-metal Stent for ST-elevation Myocardial Infarction

Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials

Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis

Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials

Bare-metal stent versus drug-eluting stent in large coronary arteries: meta-analysis of randomized controlled trials.

Mid-term treatment results of drug-eluting stent implantation for patients with multivessel chronic total coronary occlusion lesions